# Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia

> **NCT01712646** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Institute of Mental Health (NIMH)** · enrollment: 18 (actual)

## Conditions studied

- Childhood Onset Psychotic Disorders
- Schizophrenia

## Interventions

- **DRUG:** Intranasal Oxytocin

## Key facts

- **NCT ID:** NCT01712646
- **Lead sponsor:** National Institute of Mental Health (NIMH)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10-05
- **Primary completion:** 2016-06-20
- **Final completion:** —
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712646, "Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01712646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*